Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 30,787

Document Document Title
WO/2019/029274A1
Provided in the present invention are a novel compound and a preparation method therefor. The general structural formula of the compound is shown as formula I. Animal experiments prove that the compound of the present invention has the e...  
WO/2019/029613A1
A deuterated quinoline compound, specifically a compound represented by formula (I), a stereochemical isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof for use in the preparation of a medicament for treating...  
WO/2019/029273A1
A novel compound, a preparation method therefor and use thereof. The structure is as shown in formula I. Said compound can be used for preparing medicaments for treating diseases such as Alzheimer's disease, Parkinson's disease, vascular...  
WO/2019/025540A1
The invention relates to 3-acyl-benzamides of formula (I) as herbicides. In formula (I) X, Y, Z and Rx represent radicals such as alkyl, cycloalkyl and halogen.  
WO/2019/027040A1
A compound represented by formula (1) (in the formula, R1-R8, R11-R18, R21-R28, R31-R38, X, Y, L1, L2, L3, and Ar are as defined in the specification) provides an organic electroluminescent element having a low drive voltage and exceptio...  
WO/2019/027263A1
The present application provides a heterocyclic compound represented by Chemical Formula 1, and an organic light-emitting element including same.  
WO/2019/025156A1
Described are substituted pyrrolidinones of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crop cultivation and/or as plant growth regulators for influencing the growth o...  
WO/2019/022002A1
A compound represented by formula (I) or a salt thereof. (In formula (I), Q1 represents an (un)substituted C6-10 aryl group; Q2 represents an (un)substituted C1-6 alkyl group, an (un)substituted C6-10 aryl group, or a five- to ten-member...  
WO/2019/020792A1
The present invention relates to new compounds of general formula (I) that show dual activity towards α2δ subunit of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit, and to the noradrenaline transporter (NET). The...  
WO/2019/022179A1
To provide a heterocyclic compound which can exhibit an antagonistic action to NR2B subunit-containing NMDA receptors and, therefore, is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder,...  
WO/2019/020981A1
The present invention relates to substituted pyrazole, isoxazole andisothiazole compounds which are of use in the field of agriculture as fungicides.  
WO/2019/016112A1
The invention relates to 1,2,3,4-substituted quinoline compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by ...  
WO/2019/016069A1
The invention relates to substituted 5-(Het-)arylpyrazolamides of general formula (I) and to the their use as herbicides, in particular for controlling weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators...  
WO/2019/017702A1
The present invention provides a novel heterocyclic compound and an organic light-emitting diode using the same  
WO/2019/016566A1
Benzimidazole derivatives of formula (I): wherein: R1 is -(CH2)m-R4 or R2 is halo, -(CH2)m-NH2 or -(CH2)n-C(=NH)-NH2; R3 is H or F; R4 is -NH-(CH2)2-(NH)r-R5, -NH-(CHR5R6) or a group of the following formula (A): (A) W is -(CH2)m-, -CH2-...  
WO/2019/016269A1
The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.  
WO/2019/012172A1
The present invention relates to novel heteroaryl amide derivatives of formula (I), as selective inhibitors of histone deacetylase 1 and 2 (hdac1-2), to methods for the production of same, to pharmaceutical compositions comprising these ...  
WO/2019/012071A1
The present invention relates to the field of flavor or perfumery. More particularly, it concerns a composition of matter comprising : i) at least one compound of formula (I) in the form of any of its stereoisomers; and wherein R1 repres...  
WO/2019/014402A1
The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such...  
WO/2019/011166A1
The invention relates to a macrocyclic amide compound containing a thiophene group, and a preparation method of the macrocyclic amide compound and an intermediate thereof. The invention also relates to the macrocyclic amide compound cont...  
WO/2019/007696A1
The present invention discloses compounds according to Formula (I) Wherein R1, R2, L, A1, A2, A3, Cy and the subscript n are as defined herein. The present invention relates to antagonists compounds of sphingosine 1-phosphate (SIP) recep...  
WO/2019/007866A1
The invention relates to a composition comprising an electron-transporting host and a hole transporting host, to the use thereof in electronic devices and electronic devices containing said composition. The electron-transporting host is ...  
WO/2019/008152A1
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-l/PD-Ll protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative di...  
WO/2019/006548A1
A class of fluorinated 2,4-diaminopyrimidine compounds of Formula (I) have been prepared for use in the treatment of cancers and other MERTK related disorders. (Formula (I))  
WO/2019/008025A1
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...  
WO/2019/004584A1
The present invention relates to a novel compound and an organic electroluminescent device comprising the same. The compound according to the present invention is used as an organic layer of an organic electroluminescent device and, pref...  
WO/2019/004421A1
The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof. In the formula, R1 is optionally substituted C1-6 alkyl, etc.; L is -C(=O)-...  
WO/2019/004617A1
The present invention provides a novel heterocyclic compound and an organic light emitting device using the same.  
WO/2019/003141A1
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. F...  
WO/2019/002173A1
The present invention relates to a compound of formula (I): wherein the meanings for the various substituents are as disclosed in the description, having dual pharmacological activity towards both the α2δ subunit, in particular the α2...  
WO/2019/004790A1
The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting element including same.  
WO/2019/006157A1
Pyridine quinoline compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions co...  
WO/2019/000024A1
The present invention relates to certain pyridinium enolates which due to their high stokes shift find applications as fluorescent materials in solar concentrators. The invention also relates to solar concentrators containing molecules o...  
WO/2019/003142A1
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. F...  
WO/2019/004612A1
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.  
WO/2019/001572A1
The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated...  
WO/2019/000683A1
Provided are a Rho-associated protein kinase (ROCK) inhibitor of formula (I), a pharmaceutical composition containing said Rho-associated protein kinase inhibitor, a preparation method thereof and an application of the ROCK for treating ...  
WO/2019/004791A1
The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting element including same.  
WO/2019/004796A1
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.  
WO/2018/234343A1
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/234807A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections. (I)  
WO/2018/234488A1
The present invention relates to cyclopropyl compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their...  
WO/2018/235780A1
The present invention provides an organic compound represented by general formula [1]. In formula [1], Ar1 and Ar2 each represent a C1-8 alkyl group, a C6-18 aromatic hydrocarbon group, or a C3-17 aromatic heterocyclic group. The Ar1 and...  
WO/2018/235813A1
A compound represented by the formula, which has an RORγt inhibiting effect and is useful as a prophylactic or therapeutic agent for autoimmune diseases, allergic diseases, etc., or a salt thereof.  
WO/2018/234371A1
The invention relates to benzamides of formula (I), wherein Q is Q1 or Q2 or Q3 or Q4, and the other variables are as defined in the claims and the description. The invention further relates to a composition comprising such compound and ...  
WO/2018/234240A1
Compounds of formula (I), as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and co...  
WO/2018/230528A1
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...  
WO/2018/228275A1
The present invention relates to a heterocyclic compound, a pharmaceutical composition containing same, and a preparation method therefor, as well as an application of the heterocyclic compound as mitogen-activated protein kinase interac...  
WO/2018/229139A1
It relates to the compounds of formula (I), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures of stereoisomers, wherein X, L,R1, R 2, and R 3 are as defined herein, which are cancer cell differe...  
WO/2018/227067A1
The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPRl) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...  

Matches 1 - 50 out of 30,787